I pray that she carries the love that she felt tonight every day that she has," said friend Rita Monteiro, who organized the ...

Special Report: Clinical-stage biotech Neurizon Therapeutics has released positive results of preclinical studies confirming ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

Astrocytes, critical brain cells, are often lost in neurodegenerative diseases, but recent research highlights the promise of ...

Medicare is not free, even though it provides substantial assistance with medical expenses. Depending on their plan ...

Fintel reports that on November 18, 2024, Baird upgraded their outlook for Amylyx Pharmaceuticals (NasdaqGS:AMLX) from ...

Nagase Viita Co., Ltd., a member of the NAGASE Group headquartered in Okayama Japan, is set to expand the line of SOLBIOTE (TM), saccharide-based pharmaceutical excipients, with the launch of ...

Chair of the IPSF Taxonomy Working Group and Chairman of Capacity-building Alliance of Sustainable Investment (CASI), presented at several sustainable finance sessions during COP29, elaborated on ...

Morgan Stanley's latest report pegs the BCI market at $400 billion — signaling to investors that this revolutionary ...

In a report released today, Joel Beatty from Robert W. Baird upgraded Amylyx Pharmaceuticals Inc (AMLX – Research Report) to a Buy, with a ...

Needham & Company LLC reissued their buy rating on shares of Annexon (NASDAQ:ANNX – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $16.00 ...

It’s also worth mentioning that VYGR anticipates an IND submission by 2025 for its SOD1 gene therapy indicated for ...